Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for BSX
28.26
-0.02 (-0.07%)
Nov 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 28.14 - 28.37
52 week 19.67 - 29.93
Open 28.20
Vol / Avg. 5.26M/6.09M
Mkt cap 38.81B
P/E 46.62
Div/yield     -
EPS 0.61
Shares 1.37B
Beta 0.99
Inst. own 94%
Jan 31, 2018
Q4 2017 Boston Scientific Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 28, 2017
Boston Scientific Corp at Piper Jaffray Healthcare Conference - 8:30AM EST - Add to calendar
Nov 14, 2017
Boston Scientific Corp at Stifel Healthcare Conference - Webcast
Nov 7, 2017
Boston Scientific Corp at Credit Suisse Healthcare Conference - Webcast
Oct 30, 2017
Boston Scientific Corp Investor Update at Transcatheter Cardiovascular Therapeutics - Webcast
Oct 26, 2017
Q3 2017 Boston Scientific Corp Earnings Release
Oct 26, 2017
Q3 2017 Boston Scientific Corp Earnings Call - Webcast
Sep 12, 2017
Boston Scientific Corp at Morgan Stanley Healthcare Conference - Webcast
Sep 7, 2017
Boston Scientific Corp at Wells Fargo Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 12.74% 4.14%
Operating margin 16.97% 5.33%
EBITD margin - 25.70%
Return on average assets 6.13% 1.92%
Return on average equity 15.32% 5.32%
Employees 27,000 -
CDP Score - -

Address

300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Officers and directors

Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Daniel J. Brennan Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President; President, Asia-Pacific, Middle East and Africa
Age: 64
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 66
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President; President - Rhythm Management
Age: 53
Bio & Compensation  - Reuters
Edward F. Mackey Executive Vice President - Operations
Age: 54
Bio & Compensation  - Reuters
Ian T. Meredith AM Executive Vice President, Global Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President; President - MedSurg
Age: 57
Bio & Compensation  - Reuters
Desiree Ann Ralls-Morrison Senior Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters